公开(公告)号：EP1835926A4

公开(公告)日：2009-04-01

申请号：EP05849364

申请日：2005-11-22

申请人： DYAX CORP

发明人： DEVY LAETITIA ,  LEY ARTHUR ,  LADNER ROBERT C

IPC分类号： A61K38/00 ,  A61P29/00 ,  A61P35/00 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00

CPC分类号： A61K38/57 ,  A61K38/38

摘要： The disclosure features a method of treating cancers, angiogenesis-related disorders and lymphangiogenesis-related disorders with plasmin inhibitors. An exemplary method includes: administering, to a subject, a plasmin inhibitor, such as a protein that includes a Kunitz domain that inhibits plasmin.

公开(公告)号：EP1761562A4

公开(公告)日：2009-03-25

申请号：EP05723364

申请日：2005-02-22

申请人： DYAX CORP ,  CBR INST FOR BIOMED RES INC

发明人： COHEN EDWARD H ,  RONDON ISAAC J ,  SPRINGER TIMOTHY A ,  SHIMAOKA MOTOMU

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  C07K16/46

CPC分类号： C07K16/2845 ,  A61K2039/505 ,  C07K2317/32 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

公开(公告)号：EP1054018B1

公开(公告)日：2009-01-28

申请号：EP99201558.6

申请日：1999-05-18

申请人： Dyax Corp.

发明人： Hoogenboom, Hendricus Renerus Jacobus Mattheus

IPC分类号： C07K16/00 ,  C07K16/18 ,  C12N15/63 ,  C12N15/10

CPC分类号： C12N15/1037 ,  C07K16/00 ,  C07K16/005 ,  C07K16/18 ,  C07K16/26 ,  C07K16/3092 ,  C07K2317/21 ,  C07K2317/55

公开(公告)号：EP1487969A4

公开(公告)日：2008-07-09

申请号：EP02794200

申请日：2002-12-06

申请人： DYAX CORP

发明人： HOET RENE ,  HOOGENBOOM HENRICUS RENERUS JA ,  PIETERS HENK ,  LADNER ROBERT CHARLES ,  HOGAN SHANNON ,  ROOKEY KRISTIN

IPC分类号： G01N30/50 ,  B01D17/032 ,  B01D17/12 ,  B03C1/01 ,  B03C1/28 ,  C12M1/34 ,  C12N1/00 ,  C12Q1/02 ,  G01N33/569 ,  G01N35/00 ,  C12N5/06 ,  A61L2/00 ,  G01N33/533 ,  G01N33/546

CPC分类号： B03C1/01 ,  B03C1/288 ,  G01N33/56983 ,  G01N35/0098 ,  G01N2500/10

公开(公告)号：EP1687336A2

公开(公告)日：2006-08-09

申请号：EP04819225.6

申请日：2004-11-26

申请人： AstraZeneca AB ,  Dyax Corp.

发明人： NORDSTEDT, Christer, c/o AstraZeneca AB ,  GOLDSCHMIDT, Tom, c/o AstraZeneca AB ,  HENDERIKX, Maria ,  HOET, René ,  HOOGENBOOM, Hendricus ,  HUFTON, Simon ,  ANDERSSON, Christin, V., c/o AstraZeneca AB ,  LINDQUIST, Johanna, c/o AstraZeneca AB ,  SUNNEMARK, Dan, c/o AstraZeneca AB ,  LEONOV, Sergy, c/o AstraZeneca AB

IPC分类号： C07K16/00

CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2319/00

摘要： A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.

公开(公告)号：EP1660537A2

公开(公告)日：2006-05-31

申请号：EP04780912.4

申请日：2004-08-12

申请人： Dyax Corp. ,  DENDREON CORPORATION

发明人： MADISON, Edwin, L. ,  NIXON, Andrew

IPC分类号： C07K16/40 ,  A61K39/395 ,  C12N15/63 ,  C12N5/10

CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/76

摘要： This disclosure provides, inter alia, proteins that bind to ET2, e.g., immunoglobulins that inhibit ET2 with high affinity and selectivity. The ET2 binding proteins can be used to treat a variety of disorders including angiogenesis-associated disorders.

公开(公告)号：EP1656392A2

公开(公告)日：2006-05-17

申请号：EP04780886.0

申请日：2004-08-12

申请人： Dyax Corp.

发明人： HUFTON, Simon, E. ,  HOET, Rene ,  PIETERS, Henk ,  KENT, Rachel, Baribault ,  ROOKEY, Kristin

IPC分类号： C07K16/28

CPC分类号： C07K16/2863 ,  C07K16/005 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/00

摘要： Tiel is a receptor tyrosine kinase protein that includes a transmembrane domain. Tiel is present on endothelial cells. This disclosure described antibodies that bind to Tiel, including ones that inhibit endothelial cell activity.

公开(公告)号：EP1572930A2

公开(公告)日：2005-09-14

申请号：EP03737682.9

申请日：2003-02-07

申请人： Delta Biotechnology Limited ,  Dyax Corp.

发明人： HAUSER, Hans-Peter ,  WEIMER, Thomas ,  ROMBERG, Val ,  KEE, Scott, M. ,  SLEEP, Darrell ,  LADNER, Robert, Charles ,  LEY, Arthur, C.

IPC分类号： C12N1/00

CPC分类号： A61K47/48315 ,  A01K2217/05 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/00 ,  A61K38/39 ,  A61K39/00 ,  A61K39/0005 ,  A61K47/643 ,  A61K48/00 ,  A61K2039/53 ,  C07K14/005 ,  C07K14/47 ,  C07K14/765 ,  C07K14/78 ,  C07K14/8114 ,  C07K2319/00 ,  C07K2319/31 ,  C12N15/62 ,  C12N2740/16122 ,  C12Y301/26003

摘要： The invention relates to albumin fusion proteins comprising an albumin fusion partner and a protease inhibitor fusion partner which may be a Kunitz domain protease inhibitor capable of inhibiting a serine protease, including neutrophil elastase, kallikrein, and plasm The fusion proteins exhibit extended shelf life and/or extended therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits comprising the albumin fusion proteins, a well as nucleic acid molecules encoding the albumin fusion proteins, vectors comprising these nucleic acids, host cells transformed w these nucleic acids and vectors, and methods of making the encoded proteins using the nucleic acids, vectors and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin, and to compositions an methods for treating cystic fibrosis and cancer.

公开(公告)号：EP1572724A2

公开(公告)日：2005-09-14

申请号：EP03711418.8

申请日：2003-03-03

申请人： Dyax Corp. ,  BRACCO International B.V.

发明人： SATO, Aaron, K. ,  SEXTON, Daniel, J. ,  LADNER, Robert, C. ,  DRANSFIELD, Daniel, T. ,  SWENSON, Rolf, E. ,  MARINELLI, Edmund, R. ,  RAMALINGAM, Kondareddiar ,  NUNN, Adrian, D. ,  VON WRONSKI, Mathew, A. ,  SHRIVASTAVA, Ajay ,  POCHON, Sibylle ,  BUSSAT, Philippe ,  ARBOGAST, Christophe ,  PILLAI, Radhakrishna ,  FAN, Hong ,  LINDER, Karen, E. ,  SONG, Bo ,  NANJAPPAN, Palaniappa

IPC分类号： C07K7/00

CPC分类号： C07K7/08 ,  A61K38/00 ,  A61K49/223 ,  A61K51/088 ,  C07K14/001 ,  C07K14/52 ,  C07K14/71 ,  C07K2319/00 ,  Y02A50/411 ,  Y02A50/58

摘要： The present invention provides binding polypeptides for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity ( e . g ., having a K D

公开(公告)号：EP1541682A3

公开(公告)日：2005-07-06

申请号：EP05000796.2

申请日：1989-09-01

申请人： Dyax Corp.

发明人： Ladner, Robert Charles ,  Guterman, Sonia K.

IPC分类号： C12N15/10 ,  C12N15/62 ,  C12N15/73 ,  C07K16/00

CPC分类号： C40B40/02 ,  A61K38/00 ,  C07K1/107 ,  C07K14/805 ,  C07K14/8114 ,  C07K2319/70 ,  C12N15/1037

摘要： In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognise the target molecule are isolated and amplified. The successful binding domains are then characterised. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M 13 phage, and the protein includes the outer surface transport signal of the M 13 gene III protein.